# QUINTESSENTIAL-2 (NCT06615479)

> A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

No report yet. It can be ordered.

- Drugs tested: arlocabtagene autoleucel (BMS-986393)
- Indication: lenalidomide-exposed relapsed or refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06615479
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions: BMS-986393; Cyclophosphamide; Fludarabine; Daratumumab; Pomalidomide; Dexamethasone; Carfilzomib
- Enrollment: 440
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Minimal residual disease (MRD)-negativity in complete response (CR)

## Indexed commentary on QUINTESSENTIAL-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 8
- X threads: 5
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=quintessential-2-nct06615479

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06615479", "email": "<work email>"}; the inbox owner confirms by the emailed link.